# Zomedica Corp.: financial statements, quarterly

ZOMDF · OTC · CIK 1684144 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/zomdf.md) · [Financials](/companies/zomdf/financials.md) · [Filings](/companies/zomdf/filings.md) · [Insiders](/companies/zomdf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/zomdf/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.3](/filings/0001558370-24-014859.md) | [7.3 d](/filings/0001558370-25-002904.md) | [6.3](/filings/0001558370-25-007874.md) | [6.1](/filings/0001558370-25-010512.md) | [7.0](/filings/0001104659-25-106266.md) | [7.9 d](/filings/0001104659-26-028450.md) | [6.5](/filings/0001104659-26-056236.md) | [7.0](/filings/0001104659-26-091075.md) | [8.1](/filings/0001104659-25-106266.md) | [10.5 d](/filings/0001104659-26-028450.md) | [8.8](/filings/0001104659-26-056236.md) | [9.5](/filings/0001104659-26-091075.md) |
| Cost of revenue | $m | [2.0](/filings/0001558370-24-014859.md) | [2.3 d](/filings/0001558370-25-002904.md) | [2.1](/filings/0001558370-25-007874.md) | [1.8](/filings/0001558370-25-010512.md) | [1.9](/filings/0001104659-25-106266.md) | [2.3 d](/filings/0001104659-26-028450.md) | [2.1](/filings/0001104659-26-056236.md) | [2.3](/filings/0001104659-26-091075.md) | [2.7](/filings/0001104659-25-106266.md) | [3.3 d](/filings/0001104659-26-028450.md) | [3.3](/filings/0001104659-26-056236.md) | [3.5](/filings/0001104659-26-091075.md) |
| Gross profit | $m | [4.4](/filings/0001558370-24-014859.md) | [5.1 d](/filings/0001558370-25-002904.md) | [4.1](/filings/0001558370-25-007874.md) | [4.4](/filings/0001558370-25-010512.md) | [5.1](/filings/0001104659-25-106266.md) | [5.5 d](/filings/0001104659-26-028450.md) | [4.4](/filings/0001104659-26-056236.md) | [4.7](/filings/0001104659-26-091075.md) | [5.4](/filings/0001104659-25-106266.md) | [7.2 d](/filings/0001104659-26-028450.md) | [5.5](/filings/0001104659-26-056236.md) | [6.0](/filings/0001104659-26-091075.md) |
| Research and development | $m | [0.9](/filings/0001558370-24-014859.md) | [3.1 d](/filings/0001558370-25-002904.md) | [1.8](/filings/0001558370-25-007874.md) | [1.5](/filings/0001558370-25-010512.md) | [1.8](/filings/0001104659-25-106266.md) | [2.1 d](/filings/0001104659-26-028450.md) | [1.9](/filings/0001104659-26-056236.md) | [1.9](/filings/0001104659-26-091075.md) | [1.8](/filings/0001104659-25-106266.md) | [1.6 d](/filings/0001104659-26-028450.md) | [1.2](/filings/0001104659-26-056236.md) | [1.1](/filings/0001104659-26-091075.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(5.9)](/filings/0001558370-24-014859.md) | [(23.1) d](/filings/0001558370-25-002904.md) | [(10.4)](/filings/0001558370-25-007874.md) | [(25.1)](/filings/0001558370-25-010512.md) | [(7.4)](/filings/0001104659-25-106266.md) | [(8.2) d](/filings/0001104659-26-028450.md) | [(64.5)](/filings/0001104659-26-056236.md) | [(8.0)](/filings/0001104659-26-091075.md) | [(6.6)](/filings/0001104659-25-106266.md) | [(5.2) d](/filings/0001104659-26-028450.md) | [(4.9)](/filings/0001104659-26-056236.md) | [(4.1)](/filings/0001104659-26-091075.md) |
| Interest expense | $m | [0.1](/filings/0001558370-23-018830.md) | [(0.1) d](/filings/0001558370-24-007597.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(1.9)](/filings/0001558370-24-014859.md) | [0.5 d](/filings/0001558370-25-002904.md) | [(0.2)](/filings/0001558370-25-007874.md) | [(0.1)](/filings/0001558370-25-010512.md) | [(0.0)](/filings/0001104659-25-106266.md) | [(0.2) d](/filings/0001104659-26-028450.md) | [(0.1)](/filings/0001104659-26-056236.md) | [0.0](/filings/0001104659-26-091075.md) | [(0.0)](/filings/0001104659-25-106266.md) | [(0.2) d](/filings/0001104659-26-028450.md) | [0.0](/filings/0001104659-26-056236.md) | [0.0](/filings/0001104659-26-091075.md) |
| Net income | $m | [(0.5)](/filings/0001558370-24-014859.md) | [(22.4) d](/filings/0001558370-25-002904.md) | [(9.2)](/filings/0001558370-25-007874.md) | [(23.9)](/filings/0001558370-25-010512.md) | [(6.7)](/filings/0001104659-25-106266.md) | [(7.2) d](/filings/0001104659-26-028450.md) | [(63.8)](/filings/0001104659-26-091075.md) | [(7.4)](/filings/0001104659-26-091075.md) | [(6.1)](/filings/0001104659-25-106266.md) | [(4.5) d](/filings/0001104659-26-028450.md) | [(4.5)](/filings/0001104659-26-091075.md) | [(3.8)](/filings/0001104659-26-091075.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001558370-24-014859.md) | not reported | [(0.01)](/filings/0001558370-25-007874.md) | [(0.02)](/filings/0001558370-25-010512.md) | [(0.01)](/filings/0001104659-25-106266.md) | not reported | [(0.07)](/filings/0001104659-26-056236.md) | [(0.01)](/filings/0001558370-25-010512.md) | [(0.01)](/filings/0001104659-25-106266.md) | not reported | [0.00](/filings/0001104659-26-056236.md) | not reported |
| Basic EPS | $ per share | [0.00](/filings/0001558370-24-014859.md) | not reported | [(0.01)](/filings/0001558370-25-007874.md) | [(0.02)](/filings/0001558370-25-010512.md) | [(0.01)](/filings/0001104659-25-106266.md) | not reported | [(0.07)](/filings/0001104659-26-056236.md) | [(0.01)](/filings/0001104659-26-091075.md) | [(0.01)](/filings/0001104659-25-106266.md) | not reported | [0.00](/filings/0001104659-26-056236.md) | [0.00](/filings/0001104659-26-091075.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [21.8](/filings/0001558370-23-018830.md) | [13.0](/filings/0001558370-25-002904.md) | [10.9](/filings/0001558370-24-007597.md) | [7.9](/filings/0001558370-24-012228.md) | [9.7](/filings/0001558370-24-014859.md) | [7.0](/filings/0001104659-26-028450.md) | [8.8](/filings/0001558370-25-007874.md) | [8.1](/filings/0001558370-25-010512.md) | [7.5](/filings/0001104659-25-106266.md) | [9.0](/filings/0001104659-26-091075.md) | [9.4](/filings/0001104659-26-056236.md) | [7.2](/filings/0001104659-26-091075.md) |
| Current assets | $m | [115](/filings/0001558370-23-018830.md) | [99.9](/filings/0001558370-25-002904.md) | [92.1](/filings/0001558370-24-007597.md) | [89.2](/filings/0001558370-24-012228.md) | [87.3](/filings/0001558370-24-014859.md) | [81.8](/filings/0001104659-26-028450.md) | [73.2](/filings/0001558370-25-007874.md) | [68.6](/filings/0001558370-25-010512.md) | [64.7](/filings/0001104659-25-106266.md) | [64.0](/filings/0001104659-26-091075.md) | [60.0](/filings/0001104659-26-056236.md) | [57.9](/filings/0001104659-26-091075.md) |
| Total assets | $m | [275](/filings/0001558370-23-018830.md) | [253](/filings/0001558370-25-002904.md) | [244](/filings/0001558370-24-007597.md) | [220](/filings/0001558370-24-012228.md) | [214](/filings/0001558370-24-014859.md) | [207](/filings/0001104659-26-028450.md) | [143](/filings/0001558370-25-007874.md) | [136](/filings/0001558370-25-010512.md) | [131](/filings/0001104659-25-106266.md) | [127](/filings/0001104659-26-091075.md) | [122](/filings/0001104659-26-056236.md) | [118](/filings/0001104659-26-091075.md) |
| Current liabilities | $m | [6.7](/filings/0001558370-23-018830.md) | [9.0](/filings/0001558370-25-002904.md) | [8.0](/filings/0001558370-24-007597.md) | [7.8](/filings/0001558370-24-012228.md) | [8.1](/filings/0001558370-24-014859.md) | [9.3](/filings/0001104659-26-028450.md) | [7.4](/filings/0001558370-25-007874.md) | [8.1](/filings/0001558370-25-010512.md) | [8.4](/filings/0001104659-25-106266.md) | [9.4](/filings/0001104659-26-091075.md) | [8.6](/filings/0001104659-26-056236.md) | [9.0](/filings/0001104659-26-091075.md) |
| Total liabilities | $m | [14.2](/filings/0001558370-23-018830.md) | [13.2](/filings/0001558370-25-002904.md) | [11.8](/filings/0001558370-24-007597.md) | [11.2](/filings/0001558370-24-012228.md) | [11.3](/filings/0001558370-24-014859.md) | [11.7](/filings/0001104659-26-028450.md) | [10.5](/filings/0001558370-25-007874.md) | [11.1](/filings/0001558370-25-010512.md) | [11.2](/filings/0001104659-25-106266.md) | [11.6](/filings/0001104659-26-091075.md) | [10.6](/filings/0001104659-26-056236.md) | [10.9](/filings/0001104659-26-091075.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [261](/filings/0001558370-24-014859.md) | [240](/filings/0001104659-26-028450.md) | [232](/filings/0001558370-25-010512.md) | [209](/filings/0001104659-25-106266.md) | [203](/filings/0001104659-25-106266.md) | [196](/filings/0001104659-26-091075.md) | [132](/filings/0001104659-26-091075.md) | [125](/filings/0001104659-26-091075.md) | [120](/filings/0001104659-25-106266.md) | [115](/filings/0001104659-26-091075.md) | [111](/filings/0001104659-26-091075.md) | [107](/filings/0001104659-26-091075.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,027) d](/filings/0001558370-24-014859.md) | [(5,015) d](/filings/0001558370-25-002904.md) | [(7,590)](/filings/0001558370-25-007874.md) | [(6,719) d](/filings/0001558370-25-010512.md) | [(4,796) d](/filings/0001104659-25-106266.md) | [(4,525) d](/filings/0001104659-26-028450.md) | [(6,648)](/filings/0001104659-26-056236.md) | [(5,442) d](/filings/0001104659-26-091075.md) | [(4,660) d](/filings/0001104659-25-106266.md) | [(899) d](/filings/0001104659-26-028450.md) | [(5,257)](/filings/0001104659-26-056236.md) | [(2,551) d](/filings/0001104659-26-091075.md) |
| Capital expenditure | $k | [6,471 d](/filings/0001558370-24-014859.md) | [2,035 d](/filings/0001558370-25-002904.md) | [2,335](/filings/0001558370-25-007874.md) | [1,224 d](/filings/0001558370-25-010512.md) | [1,078 d](/filings/0001104659-25-106266.md) | [575 d](/filings/0001104659-26-028450.md) | [280](/filings/0001104659-26-056236.md) | [137 d](/filings/0001104659-26-091075.md) | [43.0 d](/filings/0001104659-25-106266.md) | [107 d](/filings/0001104659-26-028450.md) | [60.0](/filings/0001104659-26-056236.md) | [92.0 d](/filings/0001104659-26-091075.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [980](/filings/0001558370-23-009389.md) | [980](/filings/0001558370-23-014491.md) | [980](/filings/0001558370-23-018830.md) | [980](/filings/0001558370-24-007597.md) | [980](/filings/0001558370-24-012228.md) | [980](/filings/0001558370-24-014859.md) | [980](/filings/0001558370-25-007874.md) | [980](/filings/0001558370-25-010512.md) | [980](/filings/0001104659-25-106266.md) | [980](/filings/0001558370-25-007874.md) | [980](/filings/0001558370-25-010512.md) | [980](/filings/0001104659-25-106266.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 979,949,668 at 2026-08-05, from the cover of the [10-Q filed 2026-08-05](/filings/0001104659-26-091075.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.